Mester Alexandru, Onisor Florin, Di Stasio Dario, Piciu Andra, Cosma Adriana-Maria, Bran Simion
Department of Oral Health, University of Medicine and Pharmacy "Iuliu Hatieganu", 400006 Cluj-Napoca, Romania.
Department of Maxillofacial Surgery and Implantology, University of Medicine and Pharmacy "Iuliu Hatieganu", 400012 Cluj-Napoca, Romania.
J Pers Med. 2023 Jan 18;13(2):169. doi: 10.3390/jpm13020169.
: The aim of this systematic review with meta-analysis was to assess the performance of short implants in comparison with standard implants and sinus floor elevation in atrophic posterior maxilla. : The protocol of the study was registered in the PROSPERO database (CRD42022375320). An electronic search on three databases (PubMed, Scopus, Web of Science) was performed to find randomized clinical trials (RCTs) with ≥5 years' follow-up, published until December 2022. Risk of bias (ROB) was calculated using Cochrane ROB. A meta-analysis was performed for primary (implant survival rate, ISR) and secondary outcomes (marginal bone loss, MBL; biological and prosthetic complications). : Of 1619 articles, 5 RCTs met the inclusion criteria. The ISR showed a risk ratio (RR) of 0.97 [0.94, 1.00] (CI 95%), = 0.07. The MBL indicated a WMD of -0.29 [-0.49, -0.09] (CI 95%), = 0.005. Biological complications showed a RR of 0.46 [0.23, 0.91] (CI 95%), = 0.03. Prosthetic complications showed a RR of 1.51 [0.64, 3.55] (CI 95%), = 0.34. : The available evidence suggests that short implants might be used as an alternative to standard implants and sinus floor elevation. After 5 years, in terms of ISR, standard implants and sinus floor elevation showed a higher survival rate comparted to short implants, although statistical significance was not achieved. Future RCTs with long-term follow-up are needed to draw a clear conclusion on the advantages of one method over another.
本项带有荟萃分析的系统评价旨在评估短种植体与标准种植体以及在上颌后牙区骨萎缩时进行上颌窦底提升术相比的性能表现。本研究方案已在国际前瞻性系统评价注册库(PROSPERO数据库,注册号:CRD42022375320)登记。通过对三个数据库(PubMed、Scopus、科学网)进行电子检索,以查找随访时间≥5年且截至2022年12月发表的随机对照试验(RCT)。使用Cochrane偏倚风险评估工具计算偏倚风险(ROB)。对主要结局(种植体存留率,ISR)和次要结局(边缘骨吸收,MBL;生物学及修复并发症)进行荟萃分析。在1619篇文章中,有5项RCT符合纳入标准。种植体存留率显示风险比(RR)为0.97[0.94,1.00](95%CI),P = 0.07。边缘骨吸收显示加权均数差(WMD)为 -0.29[-0.49,-0.09](95%CI),P = 0.005。生物学并发症显示RR为0.46[0.23,0.91](95%CI),P = 0.03。修复并发症显示RR为1.51[0.64,3.55](95%CI),P = 0.34。现有证据表明,短种植体可作为标准种植体和上颌窦底提升术的替代方案。5年后,就种植体存留率而言,标准种植体和上颌窦底提升术的存留率高于短种植体,尽管未达到统计学显著性。需要未来进行长期随访的随机对照试验,以便就一种方法相对于另一种方法的优势得出明确结论。